文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

造血干细胞移植中宽松与限制性红细胞输注阈值的随机对照非劣效性III期试验

Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.
PubMed 文献 · J Clin Oncol · 2020-02-21

该多中心随机对照非劣效性试验纳入300例需造血干细胞移植的血液恶性肿瘤患者,比较限制性(血红蛋白<70 g/L)与宽松(<90 g/L)红细胞输注策略。主要终点为第100天FACT-BMT评分,限制性组非劣效于宽松组(差值1.6分,95%CI -2.5~5.6),且输注单位数更少,临床结局无显著差异。

要点

  • 限制性阈值70 g/L在移植后100天生活质量上非劣效于90 g/L。
  • 限制性策略显著减少红细胞输注量(平均2.73 vs 5.02单位)。
  • 两组移植相关死亡率、住院时间等临床结局无显著差异。

核心结论

  • 在造血干细胞移植患者中,限制性红细胞输注阈值70 g/L与宽松阈值90 g/L相比,健康相关生活质量和移植结局相似,且输血更少。

研究设计与样本

  • 研究为随机、开放标签、III期、非劣效性试验,在加拿大4个成人造血干细胞移植中心开展。
  • 2011至2016年间共随机分配300例需要造血干细胞移植的血液恶性肿瘤患者。
  • 患者随机接受限制性(血红蛋白<70 g/L)或宽松(血红蛋白<90 g/L)红细胞输注策略,干预时间为第0天至第100天。
  • 非劣效性界值为两组间FACT-BMT评分相对基线绝对差异12%。
  • 主要终点为第100天FACT-BMT评分评估的健康相关生活质量。

主要发现

  • 移植后限制性组平均输注前血红蛋白为70.9 g/L,宽松组为84.6 g/L(P < .0001)。
  • 限制性组红细胞输注单位数少于宽松组(均值2.73单位[标准差4.81] vs 5.02单位[标准差6.13];P = .0004)。
  • 调整输注类型和基线FACT-BMT评分后,限制性组第100天FACT-BMT评分更高(差值1.6分;95%CI -2.5至5.6),非劣效于宽松组。
  • 两组在临床结局方面无显著差异。

关键数值与推荐

  • 限制性输血策略定义为血红蛋白阈值<70 g/L,宽松策略定义为<90 g/L。
  • 非劣效性界值为FACT-BMT评分相对基线绝对差异12%。
  • 主要终点为第100天FACT-BMT评分。

临床怎么用

  • 对于造血干细胞移植患者,可考虑采用限制性红细胞输注阈值70 g/L以减少输血暴露。
  • 限制性策略不劣于宽松策略的生活质量和移植结局支持其临床可行性。

局限性

  • 研究仅纳入加拿大4个成人移植中心患者,外推性需谨慎。
  • 开放标签设计可能引入偏倚。
  • 非劣效性界值设定为12%绝对差异,较宽泛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evidence regarding red blood cell (RBC) transfusion practices and their impact on hematopoietic cell transplantation (HCT) outcomes are poorly understood. PATIENTS AND METHODS: We performed a noninferiority randomized controlled trial in four different centers that evaluated patients with hematologic malignancies requiring HCT who were randomly assigned to either a restrictive (hemoglobin [Hb] threshold < 70 g/L) or liberal (Hb threshold < 90 g/L) RBC transfusion strategy between day 0 and day 100. The noninferiority margin corresponds to a 12% absolute difference between groups in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) score relative to baseline. The primary outcome was health-related quality of life (HRQOL) measured by FACT-BMT score at day 100. Additional end points were collected: HRQOL by FACT-BMT score at baseline and at days 7, 14, 28, 60, and 100; transplantation-related mortality; length of hospital stay; intensive care unit admissions; acute graft-versus-host disease; Bearman toxicity score; sinusoidal obstruction syndrome; serious infections; WHO Bleeding Scale; transfusion requirements; and reactions to therapy. RESULTS: A total of 300 patients were randomly assigned to either restrictive-strategy or liberal-strategy treatment groups between 2011 and 2016 at four Canadian adult HCT centers. After HCT, mean pre-transfusion Hb levels were 70.9 g/L in the restrictive-strategy group and 84.6 g/L in the liberal-strategy group (P < .0001). The number of RBC units transfused was lower in the restrictive-strategy group than in the liberal-strategy group (mean, 2.73 units [standard deviation, 4.81 units] v 5.02 units [standard deviation, 6.13 units]; P = .0004). After adjusting for transfusion type and baseline FACT-BMT score, the restrictive-strategy group had a higher FACT-BMT score at day 100 (difference of 1.6 points; 95% CI, -2.5 to 5.6 points), which was noninferior compared with that of the liberal-strategy group. There were no significant differences in clinical outcomes between the transfusion strategies. CONCLUSION: In patients undergoing HCT, the use of a restrictive RBC transfusion strategy threshold of 70 g/L was as effective as a threshold of 90 g/L and resulted in similar HRQOL and HCT outcomes with fewer transfusions.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tay J, Allan DS, Chatelain E, et al. Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. J Clin Oncol. 2020. PMID: 32083994. doi:10.1200/JCO.19.01836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。